Moderna-2025-JPM-Presentation__Final-Website.pdf

1、 2025 Moderna,Inc.All rights reserved.43rdAnnual J.P.Morgan Healthcare ConferenceJanuary 13,2025 2025 Moderna,Inc.All rights reserved.This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,as amended,including statements regar

2、ding:Modernas 2025 revenue guidance and factors impacting the guidance range;the rate of success of Modernas platform;Modernas ability to execute on its strategic priorities,including its ability to drive use of Spikevax and mRESVIA,its focus on ten product approvals over the next three years,and it

3、s ability to deliver cost efficiency across the business to breakeven in 2028;the size and durability of the COVID-19 and RSV markets,as well as markets for potential future products;and the potential and timing for future product approvals,data readouts and commercial launches.The forward-looking s

4、tatements in this presentation are neither promises nor guarantees,and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks,uncertainties,and other factors,many of which are beyond Modernas control and which could cause actual results t

5、o differ materially from those expressed or implied by these forward-looking statements.These risks,uncertainties,and other factors include those other risks and uncertainties described under the heading“Risk Factors”in Modernas Annual Report on Form 10-K for the fiscal year ended December 31,2023,f

6、iled with the U.S.Securities and Exchange Commission(SEC),and in subsequent filings made by Moderna with the SEC,which are available on the SECs website at www.sec.gov.Except as required by law,Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements